Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winer

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
Science (New York, N.Y.)|April 9, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunityJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Neuro-Oncology|December 9, 2023
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistanceAlbert E Kim, Kevin W Lou, Anita Giobbie-Hurder, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacyAlbert E Kim, Kevin W Lou, Anita Giobbie-Hurder, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
Science (New York, N.Y.)|April 9, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunityJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Neuro-Oncology|December 9, 2023
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistanceAlbert E Kim, Kevin W Lou, Anita Giobbie-Hurder, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacyAlbert E Kim, Kevin W Lou, Anita Giobbie-Hurder, et al.
Pageof 11